Premium
A double‐blind comparison of raclopride and haloperidol in the acute phase of schizophrenia
Author(s) -
the TODAY Study Group
Publication year - 1992
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1992.tb03286.x
Subject(s) - haloperidol , extrapyramidal symptoms , raclopride , brief psychiatric rating scale , psychology , schizophrenia (object oriented programming) , rating scale , antipsychotic , psychopathology , positive and negative syndrome scale , dopamine antagonist , anesthesia , olanzapine , clinical global impression , medicine , psychiatry , psychosis , dopamine receptor d2 , placebo , dopamine , developmental psychology , alternative medicine , pathology
This is the first comparative double‐blind study of raclopride. Ninety‐one patients with acute schizophrenia received either raclopride 2‐8 mg twice daily or haloperidol 5‐20 mg twice daily for 4 weeks. Both neuroleptics produced clinical improvements. There were no significant between‐drug differences in overall efficacy measurements as assessed by the schizophrenia change sub‐scale of the Comprehensive Psychopathological Rating Scale and the Krawiecka (Manchester) Rating Scale. Assessment by the Clinical Global Impression scale found haloperidol to be more effective. There were significantly fewer extrapyramidal symptoms with raclopride and a significantly lower incidence of acute dystonia. The results suggest that raclopride has an antipsychotic effect with a low incidence of extrapyramidal side effects.